Chapter 2 - University of British Columbia

More documents

Recommendations

Info

5.2 Genomic alterations ........................................................................................................ 113 5.2.1 Chromosomal aberrations ........................................................................................ 113 5.2.2 Gene dosage, allelic imbalance, mutational status ................................................... 113 5.2.3 Genomic landscape: Gains, losses and uniparental disomy .................................... 116 5.3 Epigenomic alterations .................................................................................................... 117 5.3.1 The cancer methylome ............................................................................................. 117 5.3.2 Integration of cancer genomic and epigenomic events ............................................ 119 5.4 Relating genetic and epigenetic events to changes in the transcriptome through integrative analysis ................................................................................................................ 120 5.4.1 Multiple mechanisms of gene disruption ................................................................... 121 5.4.2 Multiple mechanisms of disrupting non-coding RNA levels ...................................... 121 5.4.3 Multi-dimensional integration of genome, epigenome, and transcriptome ............... 122 5.4.4 Disruption of multiple components in biological pathways ........................................ 124 5.4.5 Identification of a novel gene involved with EGFR signaling deregulated in adenocarcinoma ................................................................................................................ 125 5.4.6 Prevalence of SIRPA deregulation and association with clinical characteristics ...... 126 5.5 Tracking clonal expansion in spatial dimensions ............................................................ 127 5.6 Evaluating the biological significance of integrative genomics findings .......................... 127 5.5 References ...................................................................................................................... 144 Chapter 6: Conclusions ............................................................................................................. 162 6.1 Summary ......................................................................................................................... 163 6.1.1 Development of the integrative genetic and epigenetic approach ............................ 163 6.1.2 Identification of a prevalent genetic alteration in lung adenocarcinoma ................... 164 6.1.3 Application of the integrative approach to lung adenocarcinoma specimens ........... 165 6.2 Conclusions ..................................................................................................................... 166 6.3 Future directions .............................................................................................................. 168 6.4 References ...................................................................................................................... 171 APPENDIX I: List of publications .............................................................................................. 174 APPENDIX II: Description of cell lines ...................................................................................... 183 APPENDIX III: Sources of data ................................................................................................. 184 APPENDIX IV: MCD strategy and Kaplan-Meier analysis of TUSC3 ....................................... 185 APPENDIX V: Kaplan-Meier and Oncomine expression analysis of frequent MCD genes ...... 186 APPENDIX VI: Summary of Kaplan-Meier survival analysis .................................................... 188 APPENDIX VII: Copy of UBC Research Ethics Board certificate of approval........................... 189 vi
List of Tables Table 2.1. Features required for integrative analysis .................................................................. 44 Table 2.2. Summary of Input, analysis, output for each dimension ............................................ 45 Table 4.1. Regions of the genome exhibiting frequent UPD ....................................................... 99 Table 4.2. List of major oncogenes and tumor suppressor genes assessed ............................ 101 Table 4.3. Overlap of oncogenes in frequent regions of genomic alteration ............................. 102 Table 4.4. Overlap of tumor suppressor genes in frequent regions of genomic alteration ....... 103 Table 4.5. Cell lines and oncogene loci with homozygous mutation ......................................... 104 Table 4.6. Summary of homozygous mutation analysis in cancer cell lines ............................. 105 Table 4.7. RefSeq genes in focal regions of UPD .................................................................... 106 Table 4.8. Genes overexpressed in focal regions of UPD ........................................................ 107 Table 5.1. List of software for integrative analysis .................................................................... 141 Table 5.2. List of genomic resources and databases ............................................................... 142 Table 5.3. Genes interacting with SIRPA as identified by network analysis ............................. 143 vii
Page 1 and 2: DEVELOPMENT AND APPLICATION OF AN I
Page 3 and 4: Table of Contents Abstract ........
Page 5: 3.3.2 Multi-dimensional analysis (M
Page 9 and 10: Figure 5.3. Overlay of chromosomal
Page 11 and 12: RB1 Retinoblastoma 1 RNA Ribonuclei
Page 13 and 14: Dedication To my family. xiii
Page 15 and 16: Chapter 5: Chari R, Thu KL, Wilson
Page 17 and 18: 1.1 Lung cancer Lung cancer has the
Page 19 and 20: expression changes are reactive to
Page 21 and 22: number of different cancer types. M
Page 23 and 24: large number of tumors, that a give
Page 25 and 26: (B) By using an integrative approac
Page 27 and 28: platforms, with one of the latest s
Page 29 and 30: 1.12.1 Development of tools for gen
Page 31 and 32: quantitative PCR experiments as wel
Page 33 and 34: 1.13 References 1. Jemal A, Siegel
Page 35 and 36: 33. Garber ME, Troyanskaya OG, Schl
Page 37 and 38: 71. Shivapurkar N, Gazdar AF: DNA M
Page 39 and 40: Chapter 2: SIGMA 2 : A system for t
Page 41 and 42: Here, we present SIGMA 2 , a novel
Page 43 and 44: datasets. To utilize this, the user
Page 45 and 46: 2.3.7 Analysis of data from multipl
Page 47 and 48: expression (Figure 2.8). ERBB2 has
Page 49 and 50: Figure 2.1 R -Segmentation -Statist
Page 51 and 52: Figure 2.3 numSamples
Page 53 and 54: Figure 2.5. Consensus calling and h
Page 55 and 56: Figure 2.6 HCC2218 HCC2218 HCC2218B
Page 57 and 58:
Figure 2.8. Multi-dimensional persp
Page 59 and 60:
Table 2.1. Features required for in
Page 61 and 62:
2.6 References 1. Garnis C, Buys TP
Page 63 and 64:
Chapter 3: An integrative multi-dim
Page 65 and 66:
observed gene expression deregulati
Page 67 and 68:
Raw gene expression profiles from a
Page 69 and 70:
screening approach to gene amplific
Page 71 and 72:
many regions of frequent LOH/AI do
Page 73 and 74:
approach to examining the whole gen
Page 75 and 76:
PTEN expression [44]. Using this pa
Page 77 and 78:
mechanisms at the DNA and RNA level
Page 79 and 80:
In this study, three DNA dimensions
Page 81 and 82:
Figure 3.2. Quantitative and qualit
Page 83 and 84:
Figure 3.3 a Proportion of genes in
Page 85 and 86:
70 Figure 3.5 -log(pvalue) 5.0 4.0
Page 87 and 88:
72 Figure 3.7 Sample: HCC1008 Copy
Page 89 and 90:
Figure 3.8 a b Proportion of random
Page 91 and 92:
16. Chari R, Lockwood WW, Coe BP, C
Page 93 and 94:
50. Giovane A, Pintzas A, Maira SM,
Page 95 and 96:
4.1 Introduction Genetic alteration
Page 97 and 98:
4.2.3 Determining frequent regions
Page 99 and 100:
etween loss and UPD (Figure 4.3). S
Page 101 and 102:
obtained, profiled and used as the
Page 103 and 104:
Figure 4.1. Detection of UPD using
Page 105 and 106:
Figure 4.2. Comparison of frequent
Page 107 and 108:
Figure 4.3 Gain Loss 642 441 7 Figu
Page 109 and 110:
94 Figure 4.4 1 2 3 4 5 6 7 8 9 10
Page 111 and 112:
Figure 4.6 a b c Percent of cases A
Page 113 and 114:
Figure 4.7 a b 6p25.3 Log2 fold cha
Page 115 and 116:
Chr BPStart BPEnd # of Chr BPStart
Page 117 and 118:
Table 4.3. Overlap of oncogenes in
Page 119 and 120:
Table 4.5. Cell lines and oncogene
Page 121 and 122:
Table 4.7. RefSeq genes in focal re
Page 123 and 124:
4.6 References 1. Bell DW: Our chan
Page 125 and 126:
33. Garnis C, Coe BP, Lam SL, MacAu
Page 127 and 128:
5.1 Introduction In the past decade
Page 129 and 130:
polymorphism (SNP) arrays with over
Page 131 and 132:
substitutions) and UV exposure (C t
Page 133 and 134:
developed antibodies and methylated
Page 135 and 136:
Histone modification states. While
Page 137 and 138:
metastasis [226]. High throughput a
Page 139 and 140:
Implications on sample size require
Page 141 and 142:
analyzed using the "minet" package
Page 143 and 144:
expression. The next challenge is t
Page 145 and 146:
Figure 5.2 # of copies Total copy n
Page 147 and 148:
Figure 5.4. Integration of copy num
Page 149 and 150:
Figure 5.5. Integration of copy num
Page 151 and 152:
Figure 5.6 SHC1 GRB2 SOS2 RRAS ER R
Page 153 and 154:
Figure 5.8 a Log2 Fold Change (T vs
Page 155 and 156:
Figure 5.10 (a) (b) Figure 5.10. Au
Page 157 and 158:
Table 5.2. List of genomic resource
Page 159 and 160:
5.5 References 1. Pinkel D, Segrave
Page 161 and 162:
37. Oliphant A, Barker DL, Stuelpna
Page 163 and 164:
75. Selzer RR, Richmond TA, Pofahl
Page 165 and 166:
111. Melcher R, Al-Taie O, Kudlich
Page 167 and 168:
145. Takai D, Yagi Y, Wakazono K, O
Page 169 and 170:
179. Kondo M, Suzuki H, Ueda R, Osa
Page 171 and 172:
alterations in human prostate cance
Page 173 and 174:
248. Xi L, Feber A, Gupta V, Wu M,
Page 175 and 176:
281. Fernandez-Ranvier GG, Weng J,
Page 177 and 178:
Chapter 6: Conclusions 162
Page 179 and 180:
can identify nearly three times as
Page 181 and 182:
was identified in a small set of sa
Page 183 and 184:
will be done at the pathway level a
Page 185 and 186:
previously described genetic and ep
Page 187 and 188:
16. Zhang K, Li JB, Gao Y, Egli D,
Page 189 and 190:
APPENDIX I: List of publications Th
Page 191 and 192:
This publication is described in se
Page 193 and 194:
This chapter details the technologi
Page 195 and 196:
epigenetic alteration. This led to
Page 197 and 198:
This manuscript describes the curre
Page 199 and 200:
APPENDIX III: Sources of data Sampl
Page 201 and 202:
APPENDIX V: Kaplan-Meier and Oncomi
Page 203 and 204:
APPENDIX VI: Summary of Kaplan-Meie
Page 205:
University of British Columbia - Br
show all

Chapter 2 - University of British Columbia

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?